0,58 €
1,91 %
L&S, 4. Juli, 22:54 Uhr
ISIN
US22978P1066
Symbol
CUE
Berichte
Sektor
Industrie

Cue Biopharma, Inc. Aktie News

Neutral
GlobeNewsWire
5 Tage alt
ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC 12-month landmark survival of 88% and mOS of 32 months
Neutral
GlobeNewsWire
12 Tage alt
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2
Neutral
GlobeNewsWire
etwa 2 Monate alt
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments
Neutral
GlobeNewsWire
etwa 2 Monate alt
Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T ce...
Neutral
GlobeNewsWire
2 Monate alt
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Citizens Life Sciences Conference being held in N...
Neutral
Seeking Alpha
3 Monate alt
Cue Biopharma, Inc. (NASDAQ:CUE ) Business Update Call April 15, 2025 4:30 PM ET Company Participants Eric Ribner - LifeSci Advisors Dan Passeri - Chief Executive Officer Lucinda Warren - Chief Business Officer Operator Good day, and welcome to the Cue Biopharma Business Update Call. All participants are in a listen-only mode.
Neutral
GlobeNewsWire
3 Monate alt
Ingelheim, Germany, and Boston, MA, USA, April 14, 2025 – Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developi...
Neutral
GlobeNewsWire
3 Monate alt
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the pricing of an underwritten public offering of (i) 13,530,780 shares of its common stock and ac...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen